Immune Checkpoints are proteins that act as T cell receptor (TCR) co-signaling partners that deliver either positive or negative signals to T lymphocytes. Under normal conditions, these proteins are critical for self-tolerance, but in tumors, these immune checkpoint proteins can allow the tumor to evade the anti-tumor immune response. Blocking the actions of these proteins can produce a potent anti-tumor response. This new approach to cancer treatment is referred to as cancer immunotherapy or immuno-oncology.
ProSci has developed several classes of reagents that can be used to study the actions of multiple immune checkpoint proteins such as CTLA-4, PD-1, and its ligands PD-L1 and PD-L2. These classes of products include highly validated mouse monoclonal antibodies, llama single domain recombinant antibodies, rabbit polyclonal antibodies, as well as recombinant proteins, tissue and cell slides and lysates. Through these immune checkpoint research reagents, ProSci enhances basic research, diagnostics, and drug development in the field of cancer immunotherapy (Immuno-Oncology).
ProSci’s immune checkpoint monoclonal antibodies were developed to improve in vitro studies. Unlike antibodies developed using proteins made in yeast or bacteria, these antibodies are developed with antigens expressed in mammalian cell lines, giving the most native post-translational modifications to the protein. They have been extensively evaluated and are guaranteed to work for a variety of applications such as ELISA, Flow Cytometry, Western Blotting, Immunocytochemistry, Immunofluorescence, and Immunohistochemistry
Many monoclonal antibodies work well in one application but not in others despite detecting the same protein due to their specificity and how the corresponding epitope is displayed in a particular assay. Because the target epitope may be denatured or inaccessible depending on the technique, scientists often search for and test multiple antibodies for one application and repeat the process again for a different application. ProSci has recognized this issue and has released Immune Checkpoint Antibody Sets for the convenience of offering pre-packaged sample sets to allow researchers to find the optimal antibody for their application.
